Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
06 5월 2023 - 5:54AM
Edgar (US Regulatory)
SEC FILE NUMBER: 000-56199
CUSIP NUMBER: 58507M107
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM
12b-25
NOTIFICATION OF
LATE FILING
(Check One): |
☐ Form 10-K |
☐ Form 20-F |
☐ Form 11-K |
|
|
☒ Form 10-Q |
☐ Form 10-D |
☐ Form N-SAR |
☐ Form N-CSR |
For Period Ended: March
25, 2023
|
☐ |
Transition Report on Form 10-K |
|
☐ |
Transition Report on Form 20-F |
|
☐ |
Transition Report on Form 11-K |
|
☐ |
Transition Report on Form 10-Q |
|
☐ |
Transition Report on Form N-SAR |
|
|
|
|
|
|
|
For the Transition Period Ended: |
|
|
|
|
|
|
|
|
Nothing in this
form shall be construed to imply that the Commission has verified any information contained herein.
If the notification
relates to a portion of the filing checked above, identify the item(s) to which the notification relates: Not applicable.
PART I -- REGISTRANT
INFORMATION
MEDMEN
ENTERPRISES INC.
Full Name of Registrant
N/A
Former Name if Applicable
8740 S Sepulveda
Blvd, Suite 105
Address of Principal
Executive Office (Street and Number)
Los Angeles, CA 90045
City, State and Zip
Code
PART II – RULES 12b-25(b) AND (c) |
|
|
|
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.) |
|
|
|
|
(a) |
The reasons described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or expense; |
☒ |
(b) |
The subject annual report, semi-annual report, transition
report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be
filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed
on or before the fifth calendar day following the prescribed due date; and |
|
(c) |
The accountant’s statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable. |
|
|
|
|
|
PART III – NARRATIVE |
|
|
|
State below in reasonable detail why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR,
N-CSR or the transition report portion thereof, could not be filed within the prescribed time period. (Attach extra sheets
if needed.) |
MedMen Enterprises Inc. (the “Company”)
could not timely file without unreasonable effort or expense its Quarterly Report on Form 10-Q for the quarter ended March 25, 2023 because
of the ongoing review being undertaken by management. As part of the Company’s process in preparing its financial statements for
the period ended March 25, 2023, the Company identified errors related to impairment charges for long-lived assets that were no longer
in services that likely should have been written off from the books and records of the Company in the reporting period for the year ended
June 25, 2022. Based on the work we have conducted at this time, which is preliminary, unaudited and subject to change, the impact is
expected to principally involve non-cash impairment expense.
The Company is evaluating the impact of the error
on its consolidated financial statements and the extent to which the Company’s annual and quarterly consolidated financial statements
filed during the 2022 fiscal year require revision or amendment. Further, the Company is in the process of evaluating the control implications
of this error as it relates to the material weakness disclosure previously made in its Annual Report on Form 10-K for the year ended June
25, 2022.
PART IV – OTHER INFORMATION
| (1) | Name and telephone number of person to contact in regard
to this notification: |
|
Ana Bowman, Chief Financial Officer |
424 |
330-2082 |
|
Name |
(Area Code) |
(Telephone Number) |
(2) |
Have all other periodic reports required under Section 13
or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer
is no, identify report(s). |
|
☒ Yes ☐ No |
|
|
(3) |
Is it anticipated that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report
or portion thereof? |
|
☒ Yes ☐ No |
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
The Company is evaluating the impact of the error on its consolidated
financial statements and the extent to which the Company’s annual and quarterly consolidated financial statements filed during the
2022 fiscal year require revision or amendment.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Form 12b-25 includes “forward-looking statements,”
which may be identified by the use of words such as “anticipates,” “will,” “believes,” “intends,”
“plans,” “expects” and other similar words and expressions that predict or indicate future events or trends that
are not statements of historical matters. These forward-looking statements include statements and expectations about the Company’s
results, identification of errors in previous filings and the timing and impact thereof; the anticipated impact of certain accounting
errors and related matters on our results of operations and financial condition; the scope and number of material weaknesses in internal
control over financial reporting and their potential impact; the anticipated future performance of our businesses, and the timing of the
filing of the Quarterly Report on Form 10-Q for the period ended March 25, 2023. Forward-looking statements are based on information available
at the time those statements are made and/or management’s good faith belief as of that time with respect to future events, and are
subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested
by the forward-looking statements. Such risks and uncertainties include, without limitation, the risk that, upon completion of further
procedures, the financial results for the period ended March 25, 2023 are different than the results described in this Form 12b-25, the
risk that the Company is unable to complete its closing procedures in a timely manner to file its Quarterly Report on Form 10-Q as indicated
in this Form 12b-25, any potential amendments to the Company’s historical filings under the Exchange Act; the duration and scope
of the analysis of the Company’s internal control over financial reporting, including potential conclusions that there is one or
more additional material weaknesses in the Company’s internal control over financial reporting; our ability to identify and remedy
internal control weaknesses and deficiencies; that our disclosure controls and procedures are not effective; the timing and nature of
the final resolution of the accounting issues referred to in this notice and the attached explanation; our ability to become current with
our SEC periodic reporting requirements; our ability to effectively implement our business strategies and manage the risks in our business;
the reactions of the marketplace to the foregoing; the other factors discussed in this notice and the attached explanation; litigation
and potential governmental investigations or proceedings arising out of or related to accounting and financial reporting matters; general
business, economic and political conditions as well as those risks and uncertainties described in the sections entitled “Risk Factors”
in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) and
similar disclosures in subsequent periodic and current reports filed with the SEC, which are available on the SEC website at www.sec.gov.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they are made.
The Company disclaims any obligation to update or correct any forward-looking statements made herein due to the occurrence of events after
the issuance of this report except as required under federal securities laws.
MEDMEN
ENTERPRISES INC.
(Name of Registrant
as Specified in Charter)
Has caused this
notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date: |
May 5, 2023 |
|
By: |
/s/ Ana Bowman |
|
|
Ana Bowman |
|
|
Chief Financial Officer |
INSTRUCTION: The
form may be signed by an executive officer of the registrant or by any other fully authorized representative. The name and title
of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant
by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on
behalf of the registrant shall be filed with the form.
Medmen Enterprises (CE) (USOTC:MMNFF)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Medmen Enterprises (CE) (USOTC:MMNFF)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024